Clinically-Relevant Tumor Models for Cancer Drug Discovery and Development
Clinical relevance is essential in preclinical oncology and I/O studies to ensure translatability of results, and the greatest chance of downstream agent success. With rapid innovation across patient-derived, humanized, and models recapitulating other clinical features needed for immunotherapy studies, the next generation of anticancer agents can be designed, assessed, and progressed through the drug development pipeline in a more efficient manner.
Attend this symposium to explore:
- The role of modeling clinical resistance in the development of new anticancer agents
- How new, translational platforms such as tumor organoids are used to evaluate CAR-T cell therapies
- The latest breakthroughs in humanized mouse models
Who should attend?
Oncology and immuno-oncology R&D and preclinical teams from pharmaceutical and biotech companies looking to facilitate cross discipline discussions on current drug discovery and development models and techniques, and how to move forward with future approaches.
Speakers: Sylvia Boj (CSO HUB), Anthony Tolcher (CEO NEXT Oncology), Gerold Feuer (Feuer Consulting Services), Fiore Cattaruzza (Amunix Pharmaceuticals), Dean Campbell (Crown Bioscience)
Date: Wednesday, December 9
Time: 9 AM PST
Register now: Virtual US Symposium